Learn more about Dr. Julia Tchou's new approach to treating patients with early stage breast cancer, which combines immunotherapy and radiation.

Looking at a tumor’s genetic information can provide a clearer picture of a patient’s unique condition and how to best treat it.

Danielle’s genetic testing journey changed her life. Read how she’s taken charge of her health to get ahead of her family’s history of pancreatic cancer.

Medical oncologist Dr. Mark H. O’Hara explains how research on innovative immunotherapy therapies at Penn may offer hope to current and future pancreatic cancer patients.

When Denise found herself diagnosed with cancer for a second time in her young life, she found comfort in the many cancer treatment and fertility preservation options available to her at Penn Medicine. Read about her journey and the research studies that are giving her hope for her future.

A new research initiative being pioneered at Penn’s Basser Center, the BRCA Founder Outreach Study (BFOR study) is dedicated to developing and integrating new methods of genetic testing into medical care.

With advancements in immunotherapy, radiation therapy and surgical resection, Penn Medicine is making progress towards a life-extending treatment for the aggressive brain cancer, glioblastoma.

Recently, the FDA approved Azedra as the first-ever non-surgical treatment for rare neuroendocrine cancers, pheochromocytoma and paraganglioma. Learn how Penn Medicine helped bring the approval to fruition and how it may impact the future treatment of patients with rare cancers.

What causes pancreatic cancer? Why are the five-year survival rates low? How effective are treatment options? Oncologists and clinical researchers at Penn Medicine are working to answers these questions—and finding new ways of treating the disease.

Thanks to the 21st Century Cures Act, cancer research and our ability to treat rare cancers like mesothelioma are progressing. Learn how.